Karius, a Redwood City, Calif.-based developer of liquid biopsy solutions for infectious diseases, secured $165m in funding.
The round was led by SoftBank Vision Fund 21, with additional participation from General Catalyst, HBM Healthcare Investments, and existing investors Khosla Ventures and LightSpeed Venture Partners.
The company intends to use the funds to accelerate clinical studies and technology innovation.
Led by CEO Mickey Kertesz, Karius pioonered the discovery and application of microbial cell-free DNA, enabling non-invasive detection of pathogens throughout the body with its Karius® Test. The Test uses novel genomics and AI approaches to identify and measure the mcfDNA of more than 1,000 clinically relevant pathogens (including bacteria, fungi, DNA viruses, and parasites) from a single blood draw, informing doctors about the likely types and quantities of infectious microorganisms affecting their patients. The Karius Test delivers results typically the day after sample receipt, allowing doctors to diagnose and treat their patients. Today, it is used in over 100 hospitals and health systems nationwide.